Neurogene Inc (ticker: NGNE) shares surged 32% in pre-market trading after the company announced that its experimental therapy for rare neurological diseases has received "Breakthrough Therapy" designation from the U.S. Food and Drug Administration (FDA).

Neurogene Inc (ticker: NGNE) shares surged 32% in pre-market trading after the company announced that its experimental therapy for rare neurological diseases has received "Breakthrough Therapy" designation from the U.S. Food and Drug Administration (FDA).

老虎证券2026/02/27 11:24

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This designation will accelerate the development and review process of the therapy, bringing new hope for treatment to patients suffering from severe neurological diseases. Stimulated by this positive news, investor confidence has significantly increased, driving the company's stock price to surge strongly in pre-market trading.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Neurogene Inc (ticker: NGNE) shares surged 32% in pre-market trading after the company announced that its experimental therapy for rare neurological diseases has received "Breakthrough Therapy" designation from the U.S. Food and Drug Administration (FDA).

You may also like

Crypto prices